- ICH GCP
- US Clinical Trials Registry
- Search trials
Search clinical trials for: ZD6474 (Vandetanib)
Total 131 results
-
Cumberland PharmaceuticalsCompleted
-
Branimir SikicAstraZenecaCompletedColorectal Neoplasms | Anal, Colon, and Rectal Cancers | Colon/Rectal CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteTerminatedThyroid Cancer, Medullary | Thyroid Cancer | Papillary Thyroid Cancer | Differentiated Thyroid Cancer | Poorly Differentiated Thyroid Gland Carcinoma | Follicular Thyroid CancerUnited States
-
Cardiff UniversityCompletedBladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Ureter Cancer | Urethral CancerUnited Kingdom
-
SanofiCompleted
-
SanofiGenzyme, a Sanofi CompanyCompletedProstate Cancer | Metastatic | Hormone RefractoryBrazil, South Africa, Sweden, Germany, Hungary
-
Genzyme, a Sanofi CompanyCompletedNon Small Cell Lung Cancer
-
Emory UniversityCompletedHIV InfectionsUnited States
-
SanofiCompletedMedullary Thyroid CancerUnited States
-
ViiV HealthcareCompletedHIV InfectionUnited States, Spain, Portugal, Italy, Romania, Canada, Netherlands
-
UNICANCERAstraZeneca; Intergroupe Francophone de Cancerologie Thoracique; Fondation ARCCompletedNon-small Cell Lung Cancer MetastaticFrance
-
Centers for Disease Control and PreventionKenya Medical Research InstituteCompletedPneumonia | Diarrhea | HIV | Malaria | Opportunistic InfectionsKenya
-
ViiV HealthcarePfizerCompleted
-
Lucy Holmes, MDWomen & Children's Hospital of Buffalo; New York State Department of HealthCompletedAbscess | Skin Disease, BacterialUnited States
-
F2G Biotech GmbHCelerion LtdCompletedInvasive AspergillosisUnited Kingdom
-
Oslo University HospitalThe Research Council of NorwayCompleted
-
Sun Yat-sen UniversityUnknownGastrointestinal CancersChina
-
Samsung Medical CenterMinistry of Health, Republic of KoreaRecruitingRelapsed Pediatric AML | Refractory Pediatric AML | Relapsed Pediatric Solid Tumor | Refractory Pediatric Solid TumorKorea, Republic of
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7United States
-
Jennifer Lee Caswell-JinNational Cancer Institute (NCI); QED Therapeutics, Inc.TerminatedBreast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast CancerUnited States
-
Northwestern UniversityNational Cancer Institute (NCI); BHR Pharma, LLCRecruitingEstrogen Receptor Positive | Ductal Breast Carcinoma In SituUnited States
-
National Cancer Institute (NCI)CompletedStage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | Progesterone Receptor Positive | Male Breast CarcinomaUnited States
-
UNICANCERAstraZeneca; Fondation ARCActive, not recruiting
-
National Cancer Institute (NCI)Active, not recruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Multifocal Breast Carcinoma | Synchronous Bilateral Breast CarcinomaUnited States, France, Spain, Canada, Saudi Arabia, Puerto Rico, Korea, Republic of, Ireland, Colombia, Mexico
-
National Cancer Institute (NCI)NCIC Clinical Trials Group; Cancer and Leukemia Group B; North Central Cancer... and other collaboratorsActive, not recruitingHormone Receptor Positive | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIB Breast Cancer AJCC v7 | Breast AdenocarcinomaUnited States, Canada, Australia, Puerto Rico, New Zealand, Ireland, Peru, United Kingdom
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)WithdrawnStage 0 Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | HER2/Neu Negative | PostmenopausalUnited States
-
ETOP IBCSG Partners FoundationNational Cancer Institute (NCI); NCIC Clinical Trials Group; Cancer and Leukemia... and other collaboratorsActive, not recruitingRecurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor Positive Breast Cancer | Progesterone Receptor Positive TumorUnited States, Canada, Switzerland
-
National Cancer Institute (NCI)NRG OncologyCompletedRecurrent Uterine Corpus Carcinoma | Endometrial Carcinoma | Stage IIIA Uterine Corpus Cancer | Stage IIIB Uterine Corpus Cancer | Stage IVA Uterine Corpus Cancer | Stage IVB Uterine Corpus Cancer | Stage IIIC1 Uterine Corpus Cancer | Stage IIIC2 Uterine Corpus CancerUnited States
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingOvarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Recurrent Ovarian Low Grade Serous Adenocarcinoma | Borderline Ovarian Serous Tumor | Micropapillary Serous Carcinoma | Recurrent Primary Peritoneal Serous AdenocarcinomaUnited States, United Kingdom
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Breast Carcinoma | Invasive Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v6United States, Puerto Rico
-
National Cancer Institute (NCI)Eastern Cooperative Oncology Group; Canadian Cancer Trials Group; Southwest Oncology... and other collaboratorsCompletedHER2 Positive Breast Carcinoma | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Breast AdenocarcinomaUnited States, Canada, Peru, South Africa